drugset / Trial / NCT02331706

IFN-DLI for Relapsed Acute Leukemia After Allo-SCT

NCT02331706

Phase 0 Completed 16 enrolled Abramson Cancer Center at Penn Medicine
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is designed to determine the feasibility of conventional induction chemotherapy, IFNand G-CSF mobilized DLI (IFN-DLI) in subjects with relapsed AML and ALL after allo-SCT.

Timeline

Start
2014-12
Primary completion
2016-11-11
Completion
2017-11-11

Drugs

EvaluationDrugModalityDoseRoute
Subject interferon alfa-2b Protein / enzyme biologic 3e+06 iu Subcutaneous

Indications